N/A N=5,421 Medication Adherence Clinical Decision Support
Hyperlipidemia · Hypertension · Diabetes
Primary: Blood Pressure Medication Adherence — 396; 470 Participants — p=0.0103
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=9 Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)
Confirmed Genetic Diagnosis of Prader-Willi Syndrome
Primary: Percent Change From Baseline to End of Treatment in Mean Body Weight — -4.09; -0.38; 3.56; 3.00 Percent (%) change in mean body weight — p=0.1045
Phase 3 N=175 Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c) (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ — NA; 0.33; -0.17; -0.49 Percent change — p=0.2935
N/A N=40 Efficacy of Adhesive Strength of New Hydrogel Formulation
Stroke, Acute
Primary: Efficacy of the Skin Adhesive Strength of Hydrogel KM40C Compared to That of Hydrogel KM10T. — 1.52; 1.23 score on a scale
Phase 2 N=4 Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors
Adeno-Associated Virus (AAV) · Blood Coagulation Disorder · Blood Coagulation Disorders, Inherited
Primary: Number of Participants With Adverse Events (AEs) — 4 Participants
N/A N=26 Clinical Efficacy in Relief of Dyspnea by HVNI: Evaluation of New Cannulae Designs
Dyspnea · Hypercapnia · Respiratory Insufficiency
Primary: Patient Vital Signs -- Rated Perceived Dyspnea (RPD) — 3; 2.5; 2.5 units on a scale
Phase 2 N=126 Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer
Breast Cancer
Primary: Percentage of Participants Exhibiting a Pathological Complete Response (pCR) in Breast — 41.3; 54.0 percentage of participants — p=0.154
N/A N=20 Reduction and Fixation of Metatarsal Neck Fracture by Metaizeau's Technique
Displaced Metatarsal Neck Fracture
Primary: Time of Union — 5.8 weeks
N/A N=70 Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation
Atrial Fibrillation · Hypertension
Primary: Proportion of Subjects in Each Arm That Experience Safety Composite Events — 1; 3 Participants — p=0.28
Phase 2 N=6 Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
Metastatic Triple Negative Breast Cancer
Primary: Objective Response Rate (ORR) — 0; 1; 1; 4 Participants
Phase 1 N=28 A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood
Healthy
Primary: Part 1: Area Under the Concentration-time Curve of the Analyte (Rosuvastatin) in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 23.92; 25.20…
Phase 2 N=43 Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .
Colorectal Adenocarcinoma
Primary: Percentage of Patients With a Tumoral Control Rate at 2 Months — 31.4 Percentage of patients
Phase 1 N=24 Phase I/Ib Multiple Ascending Dose Study in China
Metastatic Solid Tumors
Primary: Number of Participants With of Dose-limiting Toxicities (DLTs) According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version…
Phase 1 N=39 Healthy Combine Study
Healthy
Primary: Change in Intact FGF23 — 1.001; 1.006; 1.009; 1.005 pg/ml — p=0.3738
Phase 1 N=18 A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations
Healthy
Primary: Area Under the Plasma Concentration-Time Profile From Time Zero to Extrapolated Infinite Time (AUCinf) Following Single Oral Doses of Encorafenib 75 mg Alone and With…